AnnJi Highlights Patient and Family Forum at KDA 2026 with AJ201 Updates AnnJi Pharmaceutical participated in the KDA 2026 Conference, showcasing their pioneering AJ201 development and hosting a dedicated forum for patients and families.

AnnJi Highlights Patient and Family Forum at KDA 2026 with AJ201 Updates #Taiwan #Taipei #AnnJi_Pharmaceutical #AJ201 #Kennedy_Disease

AnnJi Pharmaceutical Empowers SBMA Community at KDA 2026 Conference with Scientific Insights on AJ201 At the KDA 2026 Conference, AnnJi Pharmaceutical presented key advancements in AJ201, engaging patients and families to enhance clinical dialogue and understanding.

AnnJi Pharmaceutical Empowers SBMA Community at KDA 2026 Conference with Scientific Insights on AJ201 #Taiwan #Taipei #AnnJi_Pharmaceutical #AJ201 #SBMA

AnnJi Pharmaceutical Showcases AJ201 Advancements at 2026 KDA Conference and Empowers SBMA Community At the 2026 KDA Conference, AnnJi Pharmaceutical highlighted its commitment to the SBMA community by discussing AJ201's scientific progress and patient engagement.

AnnJi Pharmaceutical Showcases AJ201 Advancements at 2026 KDA Conference and Empowers SBMA Community #Taipei #None #AnnJi_Pharmaceutical #AJ201 #KDA_Conference

AnnJi Pharmaceutical Empowers SBMA Community at 2026 KDA Conference Through Patient Forum and Scientific Advances During the 2026 KDA Conference, AnnJi Pharmaceutical highlighted the importance of collaboration with the SBMA community while presenting groundbreaking research on AJ201.

AnnJi Pharmaceutical Empowers SBMA Community at 2026 KDA Conference Through Patient Forum and Scientific Advances #Taiwan #Taipei #AnnJi_Pharmaceutical #AJ201 #SBMA

AnnJi Pharmaceutical's Role in Advancing Treatments for SBMA at the 2026 KDA Conference Discover how AnnJi Pharmaceutical is leading the charge in SBMA treatment advancements at the 2026 KDA Conference, showcasing AJ201.

AnnJi Pharmaceutical's Role in Advancing Treatments for SBMA at the 2026 KDA Conference #Taiwan #Taipei #AnnJi_Pharmaceutical #AJ201 #SBMA

Fast Track Designation Granted for AJ201, a Breakthrough Therapy for Kennedy's Disease AnnJi Pharmaceutical's AJ201 has received Fast Track status from the FDA, marking a significant advancement for treating Kennedy's disease, a rare neuromuscular condition.

Fast Track Designation Granted for AJ201, a Breakthrough Therapy for Kennedy's Disease #Taipei #USA #AnnJi_Pharmaceutical #AJ201 #Kennedy_Disease

FDA Grants Fast-Track Status to Groundbreaking Therapy AJ201 for Kennedy's Disease AnnJi Pharmaceutical's AJ201 receives Fast-Track designation from the FDA, marking a significant advancement in treatment for Kennedy's Disease.

FDA Grants Fast-Track Status to Groundbreaking Therapy AJ201 for Kennedy's Disease #Taipei #USA #AnnJi_Pharmaceutical #AJ201 #Kennedy_Disease

AnnJi Pharmaceutical Achieves Fast Track Designation for AJ201 Targeting Kennedy's Disease AnnJi Pharmaceutical has been awarded Fast Track Designation from the FDA for AJ201, promising development in treating Kennedy's disease, a rare neuromuscular disorder.

AnnJi Pharmaceutical Achieves Fast Track Designation for AJ201 Targeting Kennedy's Disease #Taiwan #Taipei #AnnJi_Pharmaceutical #AJ201 #Kennedy_Disease

FDA's Fast Track Designation for Innovative AJ201 Therapy Marks a Milestone in Treating Kennedy's Disease The FDA has granted Fast Track Designation to AnnJi's AJ201, a pioneering therapy for Kennedy's disease, highlighting its potential to meet unmet medical needs.

FDA's Fast Track Designation for Innovative AJ201 Therapy Marks a Milestone in Treating Kennedy's Disease #Taipei #USA #AnnJi_Pharmaceutical #AJ201 #Kennedy's_Disease

FDA Grants Fast Track Designation for AJ201, A Novel Therapy for Kennedy Disease AnnJi Pharmaceutical has received Fast Track designation from the FDA for AJ201, a groundbreaking therapy aimed at treating Kennedy Disease, a rare genetic disorder.

FDA Grants Fast Track Designation for AJ201, A Novel Therapy for Kennedy Disease #Taipei #USA #AnnJi_Pharmaceutical #AJ201 #Kennedy_Disease

AnnJi Pharmaceutical Unveils Promising Clinical Results for AJ201 at WMS 2025 AnnJi Pharmaceutical's AJ201 shows positive clinical trial results for SBMA at the World Muscle Society 2025, signaling hope for patients.

AnnJi Pharmaceutical Unveils Promising Clinical Results for AJ201 at WMS 2025 #None #AJ201 #SBMA #AnnJi

AnnJi Pharmaceutical Announces Breakthrough Results of AJ201 for Spinal and Bulbar Muscular Atrophy AnnJi Pharmaceuticals has revealed promising Phase 2a clinical trial results for AJ201 targeted at Spinal and Bulbar Muscular Atrophy, presented at WMS 2025.

AnnJi Pharmaceutical Announces Breakthrough Results of AJ201 for Spinal and Bulbar Muscular Atrophy #Taiwan #Taipei #AJ201 #SBMA #AnnJi

AnnJi Pharmaceutical Unveils Promising Clinical Results for AJ201 at the 2025 World Muscle Society Congress AnnJi Pharmaceutical showcased the encouraging Phase 2a results for AJ201, a potential treatment for spinal bulbar muscular atrophy, at the WMS 2025 Congress.

AnnJi Pharmaceutical Unveils Promising Clinical Results for AJ201 at the 2025 World Muscle Society Congress #Taiwan #Taipei #AJ201 #SBMA #AnnJi

AnnJi Pharmaceutical Reveals Phase 2a Breakthrough of AJ201 for SBMA at WMS 2025 AnnJi Pharmaceutical highlighted Phase 2a results of AJ201 for spinal and bulbar muscular atrophy at WMS 2025, indicating a major step forward.

AnnJi Pharmaceutical Reveals Phase 2a Breakthrough of AJ201 for SBMA at WMS 2025 #Taiwan #Taipei #AJ201 #SBMABio #AnnJi

AnnJi Pharmaceutical Introduces Promising AJ201 Results for Rare Disorder at WMS 2025 AnnJi Pharmaceutical revealed remarkable Phase 2a results for AJ201, targeted at SBMA patients, during WMS 2025. A potential game-changer in treatment options is discussed.

AnnJi Pharmaceutical Introduces Promising AJ201 Results for Rare Disorder at WMS 2025 #Taiwan #Taipei #AnnJi_Pharmaceutical #AJ201 #SBMA

AnnJi Pharmaceutical Reports Positive Phase 1/2a Results for AJ201 in SBMA Patients AnnJi Pharmaceutical Co., Ltd. has unveiled promising outcomes from its Phase 1/2a trial of AJ201, targeting Spinobulbar Muscular Atrophy (SBMA) and showcasing significant clinical improvements.

AnnJi Pharmaceutical Reports Positive Phase 1/2a Results for AJ201 in SBMA Patients #Taiwan #Taipei #AnnJi_Pharmaceutical #AJ201 #SBMA

AnnJi Pharmaceutical Reports Positive Phase 1/2a Results for AJ201 in Treating SBMA Patients AnnJi Pharmaceutical has announced promising findings from its Phase 1/2a clinical trial of AJ201, targeting spinal and bulbar muscular atrophy (SBMA), showcasing improvements in muscle function.

AnnJi Pharmaceutical Reports Positive Phase 1/2a Results for AJ201 in Treating SBMA Patients #Taiwan #Taipei #AnnJi_Pharmaceutical #AJ201 #SBMA

AnnJi Pharmaceutical Reports Positive Phase 1/2a Results for AJ201 in SBMA Patients AnnJi Pharmaceutical has announced encouraging results from their Phase 1/2a trial of AJ201 for treating Spinal and Bulbar Muscular Atrophy, demonstrating improved patient outcomes.

AnnJi Pharmaceutical Reports Positive Phase 1/2a Results for AJ201 in SBMA Patients #Taiwan #Taipei #AnnJi_Pharmaceutical #AJ201 #SBMA

AnnJi Pharmaceutical Shines with Promising Results for AJ201 in SBMA Treatment Trials AnnJi Pharmaceutical has announced significant positive outcomes from its AJ201 trials for treating SBMA patients, marking a potential breakthrough in neuromuscular disorders.

AnnJi Pharmaceutical Shines with Promising Results for AJ201 in SBMA Treatment Trials #Taiwan #Taipei #AnnJi_Pharmaceutical #AJ201 #SBMA

AnnJi Pharmaceutical Shares Promising Phase 1/2a Results for AJ201 Targeting SBMA Patients AnnJi Pharmaceutical's Phase 1/2a clinical trial reveals encouraging outcomes for AJ201 in treating Spinal and Bulbar Muscular Atrophy. The findings suggest its continuing development could address significant medical needs.

AnnJi Pharmaceutical Shares Promising Phase 1/2a Results for AJ201 Targeting SBMA Patients #Taiwan #Taipei #AnnJi_Pharmaceutical #AJ201 #SBMA